Cantor Fitzgerald Estimates BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($4.50) for the year. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.56) per share.

A number of other equities analysts have also commented on BBIO. Oppenheimer began coverage on shares of BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Monday, December 16th. Bank of America upped their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Evercore ISI raised their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Finally, Leerink Partners lowered their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $48.08.

BridgeBio Pharma Price Performance

BBIO stock opened at $37.59 on Thursday. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $41.04. The firm’s 50-day moving average is $28.53 and its 200 day moving average is $26.81. The company has a market capitalization of $7.10 billion, a PE ratio of -15.60 and a beta of 1.05.

Institutional Trading of BridgeBio Pharma

Large investors have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new stake in shares of BridgeBio Pharma during the third quarter worth about $1,286,000. First Turn Management LLC acquired a new stake in BridgeBio Pharma during the 3rd quarter valued at approximately $10,178,000. Janus Henderson Group PLC increased its stake in shares of BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after acquiring an additional 505,481 shares during the period. Intech Investment Management LLC purchased a new position in shares of BridgeBio Pharma during the third quarter worth $1,136,000. Finally, Principal Financial Group Inc. lifted its position in BridgeBio Pharma by 1.8% during the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after purchasing an additional 19,978 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 4,156 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the transaction, the chief financial officer now owns 93,758 shares in the company, valued at approximately $2,101,116.78. This represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Neil Kumar sold 27,389 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at approximately $109,751,697.63. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 24.66% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.